Brooklyn ImmunoTherapeutics, Inc. – ‘S-4/A’ on 11/25/20 – ‘EX-101.INS’

On:  Wednesday, 11/25/20, at 6:13am ET   ·   Accession #:  1493152-20-22484   ·   File #:  333-249249

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Pre-Effective Amendment to Registration Statement – Securities for a Merger   —   Form S-4   —   SA’33
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4/A       Pre-Effective Amendment to Registration Statement   HTML   4.43M 
                - Securities for a Merger                                        
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML     58K 
 3: EX-10.16(A)  Material Contract                                  HTML     72K 
 4: EX-10.16(B)  Material Contract                                  HTML     74K 
 5: EX-10.17(A)  Material Contract                                  HTML     72K 
 6: EX-10.17(B)  Material Contract                                  HTML     58K 
 7: EX-10.17(C)  Material Contract                                  HTML     74K 
 8: EX-10.17(D)  Material Contract                                  HTML     66K 
 9: EX-10.18    Material Contract                                   HTML     74K 
10: EX-10.19(A)  Material Contract                                  HTML    235K 
11: EX-10.19(B)  Material Contract                                  HTML     61K 
12: EX-10.19(C)  Material Contract                                  HTML     72K 
13: EX-10.20    Material Contract                                   HTML    126K 
14: EX-10.21    Material Contract                                   HTML     68K 
15: EX-10.22    Material Contract                                   HTML     71K 
16: EX-10.23(A)  Material Contract                                  HTML    284K 
17: EX-10.23(B)  Material Contract                                  HTML     63K 
18: EX-10.23(C)  Material Contract                                  HTML     66K 
19: EX-10.23(D)  Material Contract                                  HTML    101K 
20: EX-10.24(A)  Material Contract                                  HTML    219K 
21: EX-10.24(B)  Material Contract                                  HTML     77K 
22: EX-10.24(C)  Material Contract                                  HTML     66K 
23: EX-23.4     Consent of Expert or Counsel                        HTML     54K 
24: EX-23.5     Consent of Expert or Counsel                        HTML     54K 
25: EX-99.1     Miscellaneous Exhibit                               HTML     53K 
27: EX-99.10    Miscellaneous Exhibit                               HTML     54K 
28: EX-99.11    Miscellaneous Exhibit                               HTML     54K 
29: EX-99.12    Miscellaneous Exhibit                               HTML     54K 
30: EX-99.13    Miscellaneous Exhibit                               HTML     54K 
26: EX-99.9     Miscellaneous Exhibit                               HTML     54K 
37: R1          Document and Entity Information                     HTML     68K 
38: R2          Condensed Consolidated Balance Sheets               HTML    171K 
39: R3          Condensed Consolidated Balance Sheets               HTML     83K 
                (Parenthetical)                                                  
40: R4          Condensed Consolidated Statements of Operations     HTML    134K 
                and Comprehensive Loss (Unaudited)                               
41: R5          Condensed Consolidated Statements of Operations     HTML     56K 
                and Comprehensive Loss (Unaudited) (Parenthetical)               
42: R6          Condensed Consolidated Statements of Shareholders'  HTML    122K 
                Equity (Unaudited)                                               
43: R7          Condensed Consolidated Statements of Cash Flows     HTML    195K 
                (Unaudited)                                                      
44: R8          Condensed Balance Sheets (Brooklyn                  HTML    144K 
                ImmunoTherapeutics, LLC)                                         
45: R9          Condensed Statements of Operations (Unaudited)      HTML    103K 
                (Brooklyn ImmunoTherapeutics, LLC)                               
46: R10         Condensed Statements of Changes in Members' Equity  HTML    149K 
                (Brooklyn ImmunoTherapeutics, LLC)                               
47: R11         Condensed Statements of Cash Flows (Brooklyn        HTML    265K 
                ImmunoTherapeutics, LLC)                                         
48: R12         Basis of Presentation                               HTML     62K 
49: R13         Organization of Company                             HTML     61K 
50: R14         Merger Agreement and Asset Purchase Agreement       HTML     60K 
51: R15         Covid-19-Update                                     HTML     59K 
52: R16         Going Concern Uncertainty                           HTML     66K 
53: R17         Summary of Significant Accounting Policies And      HTML    131K 
                Estimates                                                        
54: R18         Restricted Cash                                     HTML     59K 
55: R19         Fixed Assets, Net                                   HTML     65K 
56: R20         Fair Value of Financial Instruments                 HTML     62K 
57: R21         Accrued Compensation                                HTML     61K 
58: R22         Concentrations of Risk                              HTML     60K 
59: R23         Revenue Recognition                                 HTML    112K 
60: R24         Basic and Diluted Earnings Per Common Share         HTML     59K 
61: R25         Shareholders' Equity                                HTML    116K 
62: R26         Income Taxes                                        HTML     87K 
63: R27         Debt                                                HTML     66K 
64: R28         Long-term Debt                                      HTML     59K 
65: R29         Leases                                              HTML    110K 
66: R30         Commitments and Contingencies                       HTML     58K 
67: R31         Disposition of Site Equipment to Be Installed and   HTML     61K 
                Fixed Assets                                                     
68: R32         Software Development Costs                          HTML     60K 
69: R33         Goodwill                                            HTML     66K 
70: R34         Accumulated Other Comprehensive Income              HTML     59K 
71: R35         Recent Accounting Pronouncements                    HTML     65K 
72: R36         Retirement Savings Plan                             HTML     57K 
73: R37         Subsequent Events                                   HTML     65K 
74: R38         Organization and Description of Business            HTML     65K 
                Operations (Brooklyn ImmunoTherapeutics, LLC)                    
75: R39         Description of Business (Brooklyn                   HTML     57K 
                ImmunoTherapeutics, LLC) (10-K)                                  
76: R40         Going Concern (Brooklyn ImmunoTherapeutics, LLC)    HTML     72K 
77: R41         Basis of Presentation and Summary of Significant    HTML     72K 
                Accounting Policies (Brooklyn ImmunoTherapeutics,                
                LLC)                                                             
78: R42         Summary of Significant Accounting Policies          HTML    150K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
79: R43         Merger With NTN Buzztime, Inc (Brooklyn             HTML     59K 
                ImmunoTherapeutics, LLC)                                         
80: R44         Fair Value of Financial Instruments (Brooklyn       HTML     74K 
                ImmunoTherapeutics, LLC)                                         
81: R45         Business Combination (Brooklyn ImmunoTherapeutics,  HTML     61K 
                LLC) (10-K)                                                      
82: R46         Property and Equipment (Brooklyn                    HTML     76K 
                ImmunoTherapeutics, LLC)                                         
83: R47         Goodwill and in Process Research and Development    HTML     56K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
84: R48         Security Deposits and Other Assets (Brooklyn        HTML     58K 
                ImmunoTherapeutics, LLC)                                         
85: R49         Accrued Expenses (Brooklyn ImmunoTherapeutics,      HTML     65K 
                LLC)                                                             
86: R50         Investor Deposits (Brooklyn ImmunoTherapeutics,     HTML     55K 
                LLC) (10-K)                                                      
87: R51         Loans Payable (Brooklyn ImmunoTherapeutics, LLC)    HTML     68K 
88: R52         Loans Payable and Loans Payable to Related Parties  HTML     59K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
89: R53         Commitments and Contingencies (Brooklyn             HTML     82K 
                ImmunoTherapeutics, LLC)                                         
90: R54         Stock-Based Compensation (Brooklyn                  HTML     62K 
                ImmunoTherapeutics, LLC)                                         
91: R55         Members' Equity (Brooklyn ImmunoTherapeutics, LLC)  HTML     57K 
92: R56         Stockholders' Deficiency and Members' Equity        HTML     75K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
93: R57         Income Tax (Brooklyn ImmunoTherapeutics, LLC)       HTML    101K 
                (10-K)                                                           
94: R58         Subsequent Events (Brooklyn ImmunoTherapeutics,     HTML     72K 
                LLC)                                                             
95: R59         Summary of Significant Accounting Policies And      HTML    180K 
                Estimates (Policies)                                             
96: R60         Basis of Presentation and Summary of Significant    HTML     96K 
                Accounting Policies (Policies) (Brooklyn                         
                ImmunoTherapeutics, LLC)                                         
97: R61         Summary of Significant Accounting Policies          HTML    129K 
                (Policies) (Brooklyn ImmunoTherapeutics, LLC)                    
                (10-K)                                                           
98: R62         Summary of Significant Accounting Policies And      HTML    118K 
                Estimates (Tables)                                               
99: R63         Fixed Assets, Net (Tables)                          HTML     66K 
100: R64         Accrued Compensation (Tables)                       HTML     59K  
101: R65         Revenue Recognition (Tables)                        HTML    118K  
102: R66         Shareholders' Equity (Tables)                       HTML    100K  
103: R67         Income Taxes (Tables)                               HTML     84K  
104: R68         Leases (Tables)                                     HTML     95K  
105: R69         Goodwill (Tables)                                   HTML     63K  
106: R70         Business Combination (Tables) (Brooklyn             HTML     60K  
                ImmunoTherapeutics, LLC) (10-K)                                  
107: R71         Fair Value of Financial Instruments (Tables)        HTML     63K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
108: R72         Property and Equipment (Tables) (Brooklyn           HTML     70K  
                ImmunoTherapeutics, LLC)                                         
109: R73         Accrued Expenses (Tables) (Brooklyn                 HTML     64K  
                ImmunoTherapeutics, LLC)                                         
110: R74         Commitments and Contingencies (Tables) (Brooklyn    HTML     59K  
                ImmunoTherapeutics, LLC) (10-K)                                  
111: R75         Stockholders' Deficiency and Members' Equity        HTML     83K  
                (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)               
112: R76         Income Tax (Tables) (Brooklyn ImmunoTherapeutics,   HTML     89K  
                LLC) (10-K)                                                      
113: R77         Basis of Presentation (Details Narrative)           HTML     55K  
114: R78         Organization of Company (Details Narrative) (10-K)  HTML     61K  
115: R79         Merger Agreement and Asset Purchase Agreement       HTML     74K  
                (Details Narrative)                                              
116: R80         Covid-19-Update (Details Narrative)                 HTML     60K  
117: R81         Going Concern Uncertainty (Details Narrative)       HTML     97K  
118: R82         Going Concern Uncertainty (Details Narrative)       HTML     78K  
                (10-K)                                                           
119: R83         Summary of Significant Accounting Policies and      HTML    199K  
                Estimates (Details Narrative) (10-K)                             
120: R84         Summary of Significant Accounting Policies and      HTML     78K  
                Estimates - Schedule of Disaggregation of Revenues               
                (Details) (10-K)                                                 
121: R85         Summary of Significant Accounting Policies and      HTML     61K  
                Estimates - Schedule of Revenues Geographic                      
                Breakdown (Details) (10-K)                                       
122: R86         Summary of Significant Accounting Policies and      HTML     65K  
                Estimates - Schedule of Contract Liabilities                     
                (Details) (10-K)                                                 
123: R87         Summary of Significant Accounting Policies and      HTML     63K  
                Estimates - Schedule of Unamortized Installation                 
                Cost and Sales Commissions (Details) (10-K)                      
124: R88         Restricted Cash (Details Narrative)                 HTML     72K  
125: R89         Restricted Cash (Details Narrative) (10-K)          HTML     75K  
126: R90         Fixed Assets, Net (Details Narrative) (10-K)        HTML     56K  
127: R91         Fixed Assets, Net - Schedule of Property and        HTML     70K  
                Equipment (Details) (10-K)                                       
128: R92         Fixed Assets, Net - Schedule of Asset Geographic    HTML     59K  
                Breakdown (Details) (10-K)                                       
129: R93         Accrued Compensation - Schedule of Accrued          HTML     66K  
                Compensation (Details) (10-K)                                    
130: R94         Concentrations of Risk (Details Narrative) (10-K)   HTML     75K  
131: R95         Revenue Recognition - (Details Narrative)           HTML     62K  
132: R96         Revenue Recognition - Schedule of Disaggregates     HTML     78K  
                Material Revenue (Details)                                       
133: R97         Revenue Recognition - Schedule of Revenues          HTML     62K  
                Geographic Breakdown (Details)                                   
134: R98         Revenue Recognition - Schedule of Contract          HTML     66K  
                Liabilities (Details)                                            
135: R99         Revenue Recognition - Schedule of Unamortized       HTML     64K  
                Installation Cost and Sales Commissions (Details)                
136: R100        Basic and Diluted Earnings Per Common Share         HTML     57K  
                (Details Narrative)                                              
137: R101        Basic and Diluted Earnings Per Common Share         HTML     57K  
                (Details Narrative) (10-K)                                       
138: R102        Shareholders' Equity (Details Narrative)            HTML    102K  
139: R103        Shareholders' Equity (Details Narrative) (10-K)     HTML    171K  
140: R104        Shareholders' Equity - Schedule of Weighted         HTML     64K  
                Average Assumptions (Details)                                    
141: R105        Shareholders' Equity - Schedule of Weighted         HTML     64K  
                Average Assumptions (Details) (10-K)                             
142: R106        Shareholders' Equity - Schedule of Restricted       HTML     58K  
                Stock and Common Stock Unit Vested (Details)                     
143: R107        Shareholders' Equity - Summary of Stock Option      HTML    104K  
                Activity (Details) (10-K)                                        
144: R108        Shareholders' Equity - Summary of Restricted Stock  HTML     76K  
                Unit Activity (Details) (10-K)                                   
145: R109        Shareholders' Equity - Summary of Warrant           HTML     77K  
                Activities (Details) (10-K)                                      
146: R110        Income Taxes (Details Narrative) (10-K)             HTML     71K  
147: R111        Income Taxes - Schedule of Current and Deferred     HTML     89K  
                Income Tax Provision (Benefit) (Details) (10-K)                  
148: R112        Income Taxes - Schedule of Deferred Tax Assets and  HTML     95K  
                Liabilities (Details) (10-K)                                     
149: R113        Income Taxes - Schedule of Reconciliation of        HTML     72K  
                Expected Income Taxes (Details) (10-K)                           
150: R114        Debt (Details Narrative)                            HTML    159K  
151: R115        Long-term Debt (Details Narrative) (10-K)           HTML     88K  
152: R116        Leases (Details Narrative)                          HTML    122K  
153: R117        Leases (Details Narrative) (10-K)                   HTML     78K  
154: R118        Leases - Schedule of Operating Lease Right-of-use   HTML     79K  
                Assets and Liabilities (Details)                                 
155: R119        Leases - Schedule of Operating Lease Right-of-use   HTML     74K  
                Assets and Liabilities (Details) (10-K)                          
156: R120        Leases - Schedule of Maturities of Operating        HTML     74K  
                Leases (Details) (10-K)                                          
157: R121        Leases - Schedule of Financing Lease Right-of-use   HTML     67K  
                Assets and Liabilities (Details)                                 
158: R122        Leases - Schedule of Financing Lease Right-of-use   HTML     66K  
                Assets and Liabilities (Details) (10-K)                          
159: R123        Leases - Schedule of Maturities of Financing        HTML     64K  
                Leases (Details)                                                 
160: R124        Leases - Schedule of Maturities of Financing        HTML     65K  
                Leases (Details) (10-K)                                          
161: R125        Disposition of Site Equipment to Be Installed and   HTML     70K  
                Fixed Assets (Details Narrative)                                 
162: R126        Software Development Costs (Details Narrative)      HTML     62K  
163: R127        Goodwill (Details Narrative)                        HTML     60K  
164: R128        Goodwill (Details Narrative) (10-K)                 HTML     60K  
165: R129        Goodwill - Schedule of Goodwill (Details)           HTML     63K  
166: R130        Goodwill - Schedule of Goodwill (Details) (10-K)    HTML     64K  
167: R131        Accumulated Other Comprehensive Income (Details     HTML     57K  
                Narrative)                                                       
168: R132        Accumulated Other Comprehensive Income (Details     HTML     57K  
                Narrative) (10-K)                                                
169: R133        Retirement Savings Plan (Details Narrative) (10-K)  HTML     57K  
170: R134        Subsequent Events (Details Narrative)               HTML     63K  
171: R135        Subsequent Events (Details Narrative) (10-K)        HTML    121K  
172: R136        Going Conern (Details Narrative) (Brooklyn          HTML     68K  
                ImmunoTherapeutics, LLC)                                         
173: R137        Basis of Presentation and Summary of Significant    HTML     62K  
                Accounting Policies (Details Narrative) (Brooklyn                
                ImmunoTherapeutics, LLC)                                         
174: R138        Merger With NTN Buzztime, Inc (Details Narrative)   HTML     68K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
175: R139        Fair Value of Financial Instruments (Details        HTML     61K  
                Narrative) (Brooklyn ImmunoTherapeutics, LLC)                    
176: R140        Fair Value of Financial Instruments - Schedule of   HTML     64K  
                Fair Value of Liabilities (Details) (Brooklyn                    
                ImmunoTherapeutics, LLC)                                         
177: R141        Property and Equipment (Details Narrative)          HTML     56K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
178: R142        Property and Equipment - Schedule of Property and   HTML     68K  
                Equipment (Details) (Brooklyn ImmunoTherapeutics,                
                LLC)                                                             
179: R143        Security Deposits and Other Assets (Details         HTML     62K  
                Narrative) (Brooklyn ImmunoTherapeutics, LLC)                    
180: R144        Accrued Expenses (Details) (Brooklyn                HTML     67K  
                ImmunoTherapeutics, LLC)                                         
181: R145        Loans Payable (Details Narrative) (Brooklyn         HTML     59K  
                ImmunoTherapeutics, LLC)                                         
182: R146        Commitments and Contingencies (Details Narrative)   HTML     99K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
183: R147        Stock-Based Compensation (Details Narrative)        HTML     56K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
184: R148        Members' Equity (Details Narrative) (Brooklyn       HTML     67K  
                ImmunoTherapeutics, LLC)                                         
185: R149        Going Conern (Details Narrative) (Brooklyn          HTML     86K  
                ImmunoTherapeutics, LLC) (10-K)                                  
186: R150        Summary of Significant Accounting Policies          HTML     72K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
187: R151        Business Combination (Details Narrative) (Brooklyn  HTML     63K  
                ImmunoTherapeutics, LLC) (10-K)                                  
188: R152        Business Combination - Schedule of Purchase Price   HTML     83K  
                for Acquisition (Details) (Brooklyn                              
                ImmunoTherapeutics, LLC) (10-K)                                  
189: R153        Property and Equipment (Details Narative)           HTML     63K  
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
190: R154        Property and Equipment - Schedule of Property and   HTML     68K  
                Equipment (Details) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
191: R155        Goodwill and in Process Research and Development    HTML     59K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
192: R156        Security Deposits and Other Assets (Details         HTML     65K  
                Narrative) (Brooklyn ImmunoTherapeutics, LLC)                    
                (10-K)                                                           
193: R157        Accrued Expenses (Details) (Brooklyn                HTML     70K  
                ImmunoTherapeutics, LLC) (10K)                                   
194: R158        Investor Deposits (Details Narrative) (Brooklyn     HTML     55K  
                ImmunoTherapeutics, LLC) (10-K)                                  
195: R159        Loans Payable and Loans Payable to Related Parties  HTML    101K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
196: R160        Commitments and Contingencies (Details Narrative)   HTML    130K  
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
197: R161        Commitments and Contingencies - Schedule of Future  HTML     72K  
                Commitments of Operating Lease (Details) (Brooklyn               
                ImmunoTherapeutics, LLC)                                         
198: R162        Stockholders' Deficiency and Members' Equity        HTML    167K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
199: R163        Stockholders' Deficiency and Members' Equity -      HTML     92K  
                Schedule of Stock Option Activity (Details)                      
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
200: R164        Stockholders' Deficiency and Members' Equity -      HTML     70K  
                Schedule of Stock Options Outstanding and                        
                Exercisable (Details) (Brooklyn                                  
                ImmunoTherapeutics, LLC) (10-K)                                  
201: R165        Income Tax (Details Narrative) (Brooklyn            HTML     61K  
                ImmunoTherapeutics, LLC) (10-K)                                  
202: R166        Income Tax - Schedule of Income Tax Benefit         HTML     84K  
                (Details) (Brooklyn ImmunoTherapeutics, LLC)                     
                (10-K)                                                           
203: R167        Income Tax - Schedule of Deferred Tax Assets and    HTML     61K  
                Liabilities (Details) (Brooklyn                                  
                ImmunoTherapeutics, LLC) (10-K)                                  
204: R168        Subsequent Events (Details Narrative) (Brooklyn     HTML     61K  
                ImmunoTherapeutics, LLC) (10-K)                                  
206: XML         IDEA XML File -- Filing Summary                      XML    371K  
205: EXCEL       IDEA Workbook of Financial Reports                  XLSX    284K  
31: EX-101.INS  XBRL Instance -- ntn-20200930                        XML   3.47M 
33: EX-101.CAL  XBRL Calculations -- ntn-20200930_cal                XML    459K 
34: EX-101.DEF  XBRL Definitions -- ntn-20200930_def                 XML   2.03M 
35: EX-101.LAB  XBRL Labels -- ntn-20200930_lab                      XML   2.11M 
36: EX-101.PRE  XBRL Presentations -- ntn-20200930_pre               XML   2.34M 
32: EX-101.SCH  XBRL Schema -- ntn-20200930                          XSD    461K 
207: ZIP         XBRL Zipped Folder -- 0001493152-20-022484-xbrl      Zip    337K  

‘EX-101.INS’   —   XBRL Instance — ntn-20200930

This Exhibit is an XBRL XML File.